A novel blood test has received FDA clearance, marking a significant advancement in Alzheimer's diagnosis. Designed for individuals aged 55 and older with cognitive symptoms, the test detects amyloid plaques—a key indicator of the disease. Currently, primary care doctors diagnose Alzheimer's accurately only about 60% of the time. With the new test, researchers anticipate increasing this accuracy to over 90%. Unlike costly PET scans and invasive spinal taps, the blood test offers a simpler, accessible solution that could lead to earlier diagnoses and better patient outcomes.
The test, the first of its kind cleared by the FDA, will help doctors diagnose Alzheimer's earlier and more accurately, improving care for patients.
Specialty neurologists get it right like seventy, eighty percent of the time. With the blood test, we can get it up to over 90%.
Collection
[
|
...
]